The purpose of this study is to explore the efficacy and safety of ritlecitinib in children aged 6 to less than 12 years with alopecia areata. The study drug ritlecitinib inhibits the inflammatory processes that lead to hair loss. The study drug, ritlecitinib has been approved for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above. The study drug ritlecitinib is an investigational drug in this study because it is not approved for use in children less than 12 years. In this study, ritlecitinib is being compared with a placebo. The placebo looks like the study drug but does not contain any active ingredients. Researchers will compare the results of taking the placebo to the results of taking the study drug to see if there are any differences.

Who can Participate

severe alopecia areata (hair loss)

Study ID